ProVerum: $80 Million Series B Raised For Treating BPH
By Amit Chowdhry ● Aug 25, 2025
ProVerum Limited, a leading innovator in urological medical devices, has announced the successful completion of an $80 million Series B equity financing round. This significant capital raise is a major milestone for the company as it moves toward the commercialization of its novel treatment for benign prostatic hyperplasia (BPH), a common condition affecting millions of men worldwide. The funding round was led by MVM Partners, a well-known investment firm specializing in healthcare, with new investments from OrbiMed and the Ireland Strategic Investment Fund (ISIF). Existing investors, including Gilde Healthcare Partners, Lightstone Ventures, Atlantic Bridge, and Enterprise Ireland, also participated, demonstrating strong continued support for ProVerum’s mission.